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Background: The success of cisplatin-based (Platinol, Bristol-Myers Squibb Company, New York, NY, USA) chemo-
therapy for testicular cancer comes at the price of long-term and late effects related to healthy tissue damage. We
assessed and modelled serum platinum (Pt) decay after chemotherapy and determined relationships between long-term
circulating Pt levels and known late effects.
Patients and methods: In 99 testicular cancer survivors, treated with cisplatin-based chemotherapy, serum and 24-h
urine samples were collected during follow-up (1–13 years after treatment). To build a population pharmacokinetic model,
measured Pt data were simultaneously analysed, together with cisplatin dose, age, weight and height using the
NONMEM software. Based on this model, area under the curve between 1 and 3 years after treatment (Pt AUC1–3 years)
was calculated for each patient. Predicted long-term Pt exposure was related to renal function and to late effects of treat-
ment assessed median 9 (3–15) years after chemotherapy.
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Results: Decay of Pt was best described by a two-compartment model. Mean terminal T1/2 was 3.7 (range 2.5–5.2) years.
Pt AUC1–3 years correlated with cumulative cisplatin dose, and creatinine clearance before and 1 year after treatment. Patients
with paraesthesia had higher Pt AUC1–3 years (30.9 versus 27.0 µg/l month) compared with those without paraesthesia
(P = 0.021). Patients with hypogonadism, elevated LDL-cholesterol levels or hypertension also had higher Pt AUC1–3 years.
Conclusions: Renal function before and after cisplatin treatment is an important determinant of long-term Pt exposure.
Known long-term effects of testicular cancer treatment, such as paraesthesia, hypogonadism, hypercholesterolaemia and
hypertension, are associated with long-term circulating Pt exposure.
Key words: germ cell cancer, platinum, nephrotoxicity, long-term toxicity, BEP
introduction
Since the introduction of platinum (Pt)-based chemotherapy,
metastatic testicular cancer has become a curable disease with
an excellent prognosis. However, late effects of the treatment
may compromise the quality of life after treatment [1]. Several
studies have shown that testicular cancer survivors are prone to
develop cardiovascular morbidity and experience metabolic
changes [2, 3]. Cardiovascular risk factors, in particular clustered
in the metabolic syndrome, are more prevalent in testicular
cancer survivors compared with age-matched controls. Already
during the ﬁrst years after chemotherapy, a subgroup of testicular
cancer survivors appears to develop an adverse cardiovascular
risk proﬁle [4]. The underlying mechanisms have not yet been
elucidated.
A decade ago, Gietema et al. [5] found that long-term circulating
Pt levels remained detectable up to 20 years after cisplatin combin-
ation chemotherapy. Other studies have conﬁrmed the presence of
circulating Pt residuals in serum after Pt-based treatment [6, 7].
The role of long-term exposure to circulating Pt in the develop-
ment of cardiovascular disease in testicular cancer survivors is not
clear. Moreover, the pharmacokinetic (PK) and pharmacodynamic
characteristics of long-term decay of Pt are also largely unknown.
We hypothesised that higher exposure to circulating Pt
during follow-up is associated with a higher prevalence of late
adverse effects of treatment. The primary aim of our study was
to develop a population PK model to characterise the long-term
decay of Pt. This population PK model is based on individual
cisplatin dose, age, weight, height and body surface area at the
start of treatment combined with measured Pt concentrations in
samples collected at various time-points during follow-up after
cisplatin-based chemotherapy for testicular cancer. The second
aim was to use the PK model to determine the inﬂuence of
various treatment-related factors on the modelled decay of Pt
concentrations from individual patients and to determine the
association between estimated Pt exposure and known long-
term effects of cisplatin-based chemotherapy.
methods
study population and design
Non-seminomatous testicular cancer patients treated with cisplatin-based
chemotherapy at the University Medical Centre Groningen between 1988
and 2000 were eligible. Refractory or recurrent disease, radiotherapy, a history
of cardiovascular events before diagnosis and psychosocial issues were exclu-
sion criteria (supplementary Figure S1, available at Annals of Oncology online).
The Medical Ethics Committee of the hospital approved the study protocol
and all patients gave their written informed consent.
Between 1997 and 2002, serum and 24-h urine samples were collected at
regular follow-up visits, starting at least 1 year after treatment. The timing of
collection was diverse in order to obtain data in different phases of Pt decay.
One of the serum samples was taken simultaneously with a 24-h urine
sample. In total, 240 serum samples from 98 patients (one to three samples
per patient) were collected and analysed. Median interval between the start
of chemotherapy and the date of sample was 5.0 (range 0.9–13.2) years. A
single 24-h urine sample was collected from 91 patients, with a median inter-
val of 6.6 (range 2.8–13.2) years after chemotherapy.
Serum creatinine levels were measured before chemotherapy and 1 year
after the start of chemotherapy. Creatinine clearance (CRCL), an indicator of
renal function, was calculated using the Cockcroft-Gault formula.
At median 9 (range 3–15) years after chemotherapy, a follow-up assess-
ment was carried out at the outpatient clinic in 96 patients to assess known
late effects of treatment, such as an adverse metabolic proﬁle, presence of
paraesthesia and Raynaud’s phenomenon [2, 4].
quantiﬁcation of Pt concentration in serum and
urine
Serum and 24-h urine samples were stored at −20°C until Pt measurement.
Pt concentrations were measured in serum and urine samples by a sensi-
tive procedure during which high-pressure decomposition of samples is
followed by an adsorptive voltammetric measurement. The lower limit of
quantiﬁcation of Pt was 6 pg/g serum. Measurements were done in dupli-
cate; the coefﬁcient of variation and day-to-day variation were 6% and 5%,
respectively [5].
population PK analysis
The measured serum Pt concentrations and 24-h urinary excretion rates
were simultaneously analysed by non-linear mixed-effects modelling
(NONMEM software, Version VI, ICON Development Solutions, Hanover,
MD, USA) using a one- or two-compartment model. We assumed that the
treatment period (9–12 weeks) was negligible compared with the duration of
follow-up. Since a major fraction of the dose was excreted in the urine before
the ﬁrst measurement, the PK analysis was restricted to the fraction remain-
ing in the body after the pre-measurement phase. An apparent bioavailability
factor F1 was therefore added as a parameter in the model. We assumed that
Pt was cleared solely via urinary excretion, so the urinary excretion rate was
estimated from clearance multiplied by the estimated serum concentration.
The ﬁrst-order conditional estimation method was used throughout. PLT
Tools (PLTsoft, San Francisco, CA, USA) were used as a graphical user inter-
face. To evaluate the ﬁnal model, a bootstrap analysis was carried out, based
on 1000 sets of 99 patients each, randomly selected from the available 99
patients, and non-parametric 95% conﬁdence intervals (CIs) were obtained.
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assessment of cardiometabolic status during
follow-up
Patients were asked about the presence or absence of paraesthesia and
Raynaud’s phenomenon. Paraesthesia was scored as the presence or absence
of grade I sensory neuropathy according to Common Toxicity Criteria 2.0. It
was deﬁned as the presence of abnormal cutaneous sensations of tingling,
numbness, pressure, cold and warmth that are experienced in the absence of
a stimulus. The development of Raynaud’s phenomenon after chemotherapy
was deﬁned as occurrence of peripheral discomfort and at least biphasic skin
colour change in ﬁngers or hands (or toes or feet) after cold exposition, since
start of treatment.
Body weight and height, waist and hip circumference, and blood pressure
were measured during a physical examination at the outpatient clinic. Lipids,
testosterone, luteinizing hormone (LH) and von Willebrand factor (vWF)
were measured in blood samples. All blood samples were drawn in the
morning after an overnight fast.
Hypogonadism was deﬁned as serum testosterone <10 nmol/l or LH >10
U/l or use of testosterone suppletion (with exclusion of patients using sup-
pletion because of bilateral orchidectomy). Increased low-density lipoprotein
(LDL) cholesterol was deﬁned as LDL-cholesterol >4.1 mmol/l or use of
statins (National Cholesterol Education Program—Adult Treatment Panel
III, NCEP-ATP III) [8]. Hypertension was deﬁned as newly diagnosed, i.e.
after chemotherapy, blood pressure ≥130/85 mmHg or use of antihyperten-
sive medication (metabolic syndrome criteria, American Heart Association/
National Heart, Lung, and Blood Institute) [9].
statistical analysis
Continuous variables were described with median and range. Categorical
variables were described with counts and proportions. Levels of lipids,
insulin, glucose, testosterone and vWF were non-normally distributed and
were log-transformed for statistical analysis. Univariate analysis was
carried out with the Student’s t-test. Associations between two continuous
variables were assessed by the Pearson’s correlation coefﬁcient. Linear-by-
linear association χ2 test was used to test categorical distributions.
Multiple logistic regression analyses on the presence of paraesthesia,
Raynaud’s phenomenon, hypogonadism, increased LDL-cholesterol and
increased blood pressure were carried out to assess the effect of long-term
Pt exposure and adjust for age, body mass index (BMI) and renal function.
All tests were carried out two-sided and conducted at the 0.05 signiﬁcance
level. Statistical analyses were carried out using IBM SPSS version 20 (IBM,
Chicago, IL, USA).
results
Characteristics of the study population are summarised in Table 1.
The median cumulative dose of cisplatin was 809 (range 554–1713)
mg. Measured serum Pt concentrations are shown in Figure 1.
Circulating Pt levels declined rapidly between 1 and 3 years after
treatment.
population PK model
In addition to the measured serum Pt concentrations and urinary
excretion rates, administered cumulative cisplatin dose (mg/m²,
converted to amount Pt in mg), age at the start of chemotherapy
(years), body surface area (m²), height (m) and weight (kg) were
included in the population PK analysis. The observed decay in Pt
levels was best described by a two-compartment model with log-
normally distributed interindividual variability in CL (clearance),
V2 (volume of peripheral compartment) and F1 (apparent
bioavailability). Interindividual variability in V1 (volume of
central compartment) and Q (intercompartmental clearance), or
inclusion of demographic covariates (including age, weight and
height), did not result in signiﬁcant improvement of the objective
function value. Proportional residual error in the ﬁnal model was
34%, which is acceptable and comparable with other long-term
PK models [10]. Mean terminal T1/2 was 3.7 (range 2.5–5.2)
years. The ﬁnal population PK model is summarised in supple-
mentary Table S1, available at Annals of Oncology online.
Based on themodel, the individual Pt concentration curve for each
patient was calculated using the two-compartment model equation
ðCt ¼ F1  Dose=V1  ðC1  eðl1tÞ þ C2  eðl2tÞÞÞ, where
C1, C2, λ1 and λ2 are the fractional coefﬁcients and exponents of
the corresponding bi-exponential equation. The median curve for
the total study population is depicted in Figure 1. Subsequently,
based on the model equation, individual Pt concentrations were
calculated for every patient at different moments in time
Table 1. Demographic, diagnostic, treatment-related and follow-up
characteristics of study participants
Study population characteristics n/median %/range
Cohort size 96
Age at start chemotherapy (years) 29 17–53
Age at follow-up (years) 39 23–64
Year of treatment 1988–2000









4× BEP 32 33
4× EP 8 8
3× BEP/1× EP 50 52
Other cisplatin-based regimen 6 6
Cumulative cisplatin dose (mg) 809 554–1713
Cumulative cisplatin dose (mg/m2) 400 275–800
Prevalence of late effects of treatment n a
Persisting paraesthesia 33 35
Raynaud’s phenomenon 23 25
Hypogonadism (T < 10 nmol/l or LH >10 U/l
or suppletion)
19 20
Hypercholesterolaemia (≥6.5 mmol/l or
statin)
23 25
Increased LDL-cholesterol (≥4.1 mmol/l
or statin)
37 40
Increased blood pressure (≥130/85 mmHg or
antihypertensive)
63 68
BEP: bleomycin, etoposide and cisplatin; EP: etoposide and cisplatin;
IGCCCG: International Germ Cell Cancer Collaborative Group
Classification; T: testosterone; LH: luteinizing hormone, LDL: low-
density lipoprotein.
aPercentages for individual characteristics calculated on total
number of participants on whom information was available.
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(supplementary Table S2, available at Annals of Oncology online).
The area under the curve (AUC, μg/l months) between 1 and 3
years after chemotherapy (Pt AUC1–3 years) was calculated and
used as an estimate of long-term exposure to Pt.
treatment and renal function as determinants
of long-term Pt exposure
The total administered dose cisplatin (mg) correlated signiﬁ-
cantly with long-term Pt AUC1–3 years (r = 0.517, P < 0.001;
supplementary Table S3, available at Annals of Oncology
online). Age at the start of chemotherapy correlated with long-
term Pt AUC, but this correlation disappeared after adjusting
for renal function. No correlation was found between Pt
AUC1–3 years and weight, BMI and body surface area at the
start of chemotherapy.
Median serum creatinine level before chemotherapy was sig-
niﬁcantly lower than 1 year after chemotherapy (74 versus 86
μmol/l, P < 0.001). At the follow-up visit median 9 (range 3–15)
years after treatment, median serum creatinine was 88 μmol/l.
Pt AUC1–3 years was negatively correlated with CRCL before
chemotherapy (r = −0.213, P = 0.040). Also, Pt AUC1–3 years
correlated negatively with CRCL 1 year after chemotherapy
(r =−0.272, P = 0.008) and at follow-up (r =−0.276, P = 0.007).
AUC values in different groups based on renal function and
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Figure 1. Circulating serum platinum measurements (n = 240) and predicted curves 1–13 years after chemotherapy according to the population pharmacoki-
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Figure 2. Platinum area under the curve (AUC1–3 years) after chemotherapy in different groups based on renal function and cumulative administered cisplatin
dose.
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Patients were divided into quartiles based on change in serum
creatinine 1 year after start in comparison with pre-chemotherapy.
Patients in the highest quartile, corresponding with the highest
increase in serum creatinine, had a higher Pt AUC1–3 years
(P = 0.037; supplementary Table S3, available at Annals of Oncology
online). Seventy-one patients had retroperitoneal lymph node
dissection (RPLND) as part of their treatment. Kidney function
and long-term Pt levels were comparable between the groups
with and without RPLND (data not shown).
late toxicity and long-term Pt exposure
paraesthesia and Raynaud’s phenomenon. The presence of
paraesthesia and Raynaud’s phenomenon stratiﬁed by quartiles
of Pt AUC1–3 years is depicted in supplementary Figure S2,
available at Annals of Oncology online. Patients who reported
persisting paraesthesia at follow-up had a higher Pt AUC1–3 years
(supplementary Table S4, available at Annals of Oncology online).
In a multivariate model including age and BMI at follow-up and
renal function after 1 year, a higher Pt AUC1–3 years was associated
with an increased risk for persisting paraesthesia [odds ratio
(OR) = 1.07 (95% CI 1.00–1.13), P = 0.043; supplementary
Table S5, available at Annals of Oncology online]. Pt AUC1–3 years
was not associated with the presence of Raynaud’s phenomenon.
hypogonadism. Patients with hypogonadism at follow-up had
a higher Pt AUC1–3 years (supplementary Table S4, available at
Annals of Oncology online). In the multivariate logistic regression
model, long-term exposure to Pt was signiﬁcantly associated with
hypogonadism [OR 1.10 (95% CI 1.02–1.18), P = 0.016;
supplementary Table S5, available at Annals of Oncology online].
hypercholesterolaemia. Long-term Pt exposure was higher in
patients with increased LDL-cholesterol (supplementary
Table S4, available at Annals on Oncology online). Pt AUC1–3 years
correlated with total cholesterol and LDL-cholesterol in
univariate analysis (r = 0.229, P = 0.038 and r = 0.249, P = 0.022,
respectively; supplementary Table S6, available at Annals of
Oncology online). In the multiple logistic regression model, a
higher long-term exposure to Pt remained signiﬁcantly associated
with an increased LDL-cholesterol [OR 1.07 (95% CI 1.00–1.13),
P = 0.040; supplementary Table S5, available at Annals of
Oncology online].
blood pressure. Pt AUC1–3 years was higher in patients with newly
diagnosed, i.e. post-chemotherapy, hypertension (supplementary
Table S4, available at Annals of Oncology online). Systolic blood
pressure and pulse pressure correlated with Pt AUC1–3 years
(r= 0.307, P= 0.007, respectively, r= 0.237, P= 0.038; supplementary
Table S6, available at Annals on Oncology online). In the multiple
logistic regression analysis on hypertension, the association between
Pt AUC1–3 years and hypertension remained signiﬁcant [OR = 1.10
(95% CI 1.01–1.18), P = 0.027].
discussion
In this study, we found that circulating Pt levels after cisplatin-
based chemotherapy for testicular cancer correlate strongly with
the cumulative administered cisplatin dose and renal function
before and after chemotherapy. We found a clear relationship
between long-term circulating Pt levels and well-known long-
term and late effects, such as paraesthesia, hypogonadism,
higher LDL-cholesterol levels and hypertension.
With data from this cohort, we built a population PK model
to generate new insights into the long-term decay of Pt after
cisplatin-based chemotherapy. Decay of Pt was modelled using
sequential measurements of Pt levels in serum and urine com-
bined with the administered dose of cisplatin, age, weight and
height at the start of chemotherapy. The population modelling
approach allows the prediction of serum Pt concentrations at
any time-point and AUC over any time-period for each individ-
ual patient, as used in the statistical analysis, irrespective of the
actual time-points of blood and urine sampling. This allowed us
to quantify the relationship between estimated exposure to Pt,
renal function and known late effects of treatment.
Previously, Gietema et al. [5] detected circulating Pt in serum
of patients up to 20 years after chemotherapy. Concentrations of
Pt correlated with cisplatin dose and CRCL before chemother-
apy. Brouwers et al. [6] reported comparable ﬁndings in patients
with diverse tumour types, 0.7–6 years after chemotherapy with
cisplatin or oxaliplatin. Sprauten et al. [7] quantiﬁed Pt in serum
in a cross-sectional study in 169 testicular cancer patients 4–19
years after treatment. These data indicate an association between
long-term circulating Pt levels and severity of observed neurotox-
icity in testicular cancer survivors.
Based on our PK model, we conclude that renal function,
both before and shortly after treatment, is a strong determinant
of long-term exposure to circulating Pt. In addition, patients
with a stronger increase in serum creatinine levels 1 year after
treatment compared with baseline had higher Pt AUCs during
follow-up. The relationship between circulating Pt and renal
function may act both ways: patients with higher Pt levels have
relatively more renal damage, which in turn decreases clearance.
Loss of renal function can persist after treatment of years [11].
Recently, Lauritsen et al. [12] concluded that renal function
after treatment is closely related to the number of cycles of BEP
(bleomycin, etoposide and cisplatin). These ﬁndings underscore
the importance of optimising renal function before treatment,
preserving it during treatment and preventing decline in renal
function after completion of cisplatin treatment.
Patients reporting persisting paraesthesia median 9 years after
treatment had a higher Pt AUC than those without paraesthesia.
In our study, the collection of sequential serum and urine
samples enabled us to model exposure to circulating Pt, which is
an advantage in comparison with the cross-sectional study of
Sprauten et al. The exact pathogenesis of long-term neuropathy
is unknown, but relatively high Pt levels have been found in the
dorsal root in post-mortem studies [13]. To which extent levels
of circulating Pt correspond with levels in the dorsal root is
unknown. We did not ﬁnd a relationship between Pt levels and the
presence of Raynaud’s phenomenon. Bleomycin is probably a more
important causative agent in the pathogenesis of Raynaud [14].
Hypogonadism and hyperlipidaemia are frequently observed in
testicular cancer survivors [15, 16], and are especially prevalent in
patients treated with cisplatin-containing chemotherapy (17%–
21%) [2, 4]. The higher Pt levels observed in patients with hypo-
gonadism and hyperlipidaemia could point to long-term toxicity
on healthy tissue involved in androgen- and lipid metabolism due
to Pt residuals. From post-mortem studies in cisplatin-treated
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patients, it is known that Pt residuals can be found in fat tissue,
bone and a range of organs such as liver, kidney and lungs [17].
Direct toxic effects of circulating Pt on blood vessels might result
in endothelial activation, an inﬂammatory response or accelerated
atherosclerosis. Testicular cancer survivors show signs of endothe-
lial damage, such as microalbuminuria, increased plasma levels of
endothelial and inﬂammatory marker proteins and increased
levels of circulating endothelial cells [18, 19]. In vitro experiments
demonstrate that cisplatin induces alterations in the function of
endothelial cells regarding proliferation, inﬂammation and ﬁbrin-
olysis upon exposure to Pt [20]. The association we found between
blood pressure and Pt exposure indicates that circulating Pt might
indeed have a long-term toxic effect on endothelial tissue.
Another serious long-term toxic effect of Pt-based chemother-
apy is secondary malignancies. It is conceivable that long-term Pt
contributes signiﬁcantly to the development of secondary malig-
nancies, such as urothelial cell cancer, but the limited size of our
study population does not allow us to draw conclusions on this
issue [21].
Strong points of this study are the sequential collection of
serum and urine samples per individual patient, the long-term
follow-up and the well-deﬁned phenotype. An inherent limitation
of our study is that the Pt AUC values are model-predicted values.
Cisplatin-based chemotherapy is an essential part of the suc-
cessful treatment of testicular cancer and is also used as curative
treatment in other tumour types, such as head and neck cancer
and cervical cancer. Treatment-related late effects are inevitable,
but the treatment strategy should minimise the risk of late mor-
bidity. In cases where cisplatin is administered in an adjuvant
setting, clinicians should take into account that Pt residuals may
result in long-term side-effects. Owing to the potential beneﬁcial
effect on Pt levels and the association with lower long-term Pt
exposure, optimal preservation of renal function—before, during
and after treatment—should be a priority.
In conclusion, we found a relationship between long-term Pt
exposure in testicular cancer survivors and known late effects,
such as persistent paraesthesia, hypogonadism, hypercholes-
terolaemia and increased blood pressure. This association
between healthy tissue damage in cancer survivors and long-
term Pt exposure should be considered during treatment deci-
sions and follow-up care in testicular cancer patients. Hence,
further research on healthy tissue damage caused by long-
term Pt exposure is needed.
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